143 related articles for article (PubMed ID: 12040294)
1. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
Braud AC; Levy E; Feuilhade F; Otmezguine Y; Calitchi E; Kirova Y; Le Bourgeois JP
Am J Clin Oncol; 2002 Jun; 25(3):303-7. PubMed ID: 12040294
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
3. [A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer].
Chen CM; Shen KW; Liu GY; Wu J; Lu JS; Zhuang CJ; Han QX; Liu BL; Shao ZM; Shen ZZ
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):745-7. PubMed ID: 16836921
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.
Esteban E; de Sande G; Puertas J; Fra J; Palacio I; Vieitez JM; Fernández JL; Muñiz I; Modollel A; Carrasco J; Sala M; Lacave AJ
Breast Cancer Res Treat; 2000 Jul; 62(2):127-33. PubMed ID: 11016750
[TBL] [Abstract][Full Text] [Related]
6. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin/vinorelbine as first line therapy in metastatic breast cancer.
Baldini E; Tibaldi C; Chiavacci F; Di Lieto M; Fioretto L; Giallom-bardo A; Taviani R; Ghezzi P; Bolognini A; Conte P
Breast Cancer Res Treat; 1998 May; 49(2):129-34. PubMed ID: 9696395
[TBL] [Abstract][Full Text] [Related]
8. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
[TBL] [Abstract][Full Text] [Related]
10. Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer.
Livi L; Paiar F; Santini R; De Luca Cardillo C; Galardi A; Di Cosmo D; Borghesi S; Agresti B; Nosi F; Gavilli S; Biti GP
Anticancer Drugs; 2006 Oct; 17(9):1081-5. PubMed ID: 17001182
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
Chua S; Smith IE; A'Hern RP; Coombes GA; Hickish TF; Robinson AC; Laing RW; O'Brien ME; Ebbs SR; Hong A; Wardley A; Mughal T; Verrill M; Dubois D; Bliss JM;
Ann Oncol; 2005 Sep; 16(9):1435-41. PubMed ID: 15946977
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer.
Garrone O; Principe E; Occelli M; Mercuri M; Numico G; Granetto C; Di Costanzo G; Rattazzi PD; Merlano M
Anticancer Drugs; 2004 Jan; 15(1):23-7. PubMed ID: 15090739
[TBL] [Abstract][Full Text] [Related]
15. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
[TBL] [Abstract][Full Text] [Related]
16. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.
Van Praagh I; Cure H; Leduc B; Charrier S; Le Bouedec G; Achard JL; Ferriere JP; Feillel V; De Latour M; Dauplat J; Chollet P
Oncologist; 2002; 7(5):418-23. PubMed ID: 12401904
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial.
Elomaa I; Joensuu H; Blomqvist C
Acta Oncol; 2003; 42(4):309-14. PubMed ID: 12899502
[TBL] [Abstract][Full Text] [Related]
19. [Study on predictors of long term results for neo-adjuvant chemotherapy in locally advanced breast cancer].
Huang O; Chen CM; Wu JY; Hu Z; Hou YF; Zhang JX; Liu GY; Di GH; Lu JS; Wu J; Shao ZM; Shen ZZ; Shen KW
Zhonghua Wai Ke Za Zhi; 2009 Apr; 47(7):511-5. PubMed ID: 19595208
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
